The answer is no, I don't. I'm not familiar enough with the literature around pre-market regulation, and so I would have to defer to my colleagues who are experts in regulatory process and impact.
I would note, however, that there are reasons, for instance, why countries like France and elsewhere have lots of drugs listed. In part, it's part of the global licensing and marketing strategies of drug companies, and that is to get a drug into a market like France first, where they are able to secure higher prices and actually get approvals slightly more readily than elsewhere. That creates a precedent, if you will.
If they first attempt to license in a country that is deemed to have a difficult or tough regulatory stance—and arguably, the United States is actually one of those countries—and are turned down, it sets a poor international precedent for them.
There are lots of drugs in some countries, in part not because the consumers in those countries really need thousands of medicines, but because they need to get them on the market there first and then proliferate from there.